The effect of a symptom related "gating policy" on ANCA requests in routine clinical practice

Journal of Clinical Pathology

Volumn 57, Issue 2, 2004, Pages 131-134

  Sinclair, D ^a   Saas, M ^a   Stevens, J M ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANTIBODY DETECTION; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE POLICY; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOLOGY; LABORATORY DIAGNOSIS; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SAMPLE; SCREENING TEST; SYMPTOM; SYSTEMIC VASCULITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOLOGICAL MARKERS; ENGLAND; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GATEKEEPING; HEALTH CARE RATIONING; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES; UNNECESSARY PROCEDURES; VASCULITIS;

EID: 0842265689     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2003.8052     Document Type: Article

References (13)

1. Davies DJ, Moran JE, Niall JF, et al. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? BMJ 1982;285:606.
2. Terjung B, Worman HJ, Herzog V, et al. Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy. Clin Exp Immunol 2001;126:37-46.
3. De Rosa FG, Amoroso A, Teggi A, et al. Anti-neutrophil cytoplasmic antibodies in Echinococcus granulosus hydatid disease. Hum Immunol 2001;62:1122-6.
4. Manolova I, Dancheva M, Halacheva K. Antineutrophil cytoplasmic antibodies in patients with systemic lupus erythematosus: prevalence, antigen specificity, and clinical associations. Rheumatol Int 2001;20:197-204.
5. Hoffman MD. Pyoderma gangrenosum associated with c·ANCA (h-lamp-2). Int J Dermatol 2001;40:135-7.
6. Edgar JDM, McMillan SA, Bruce IN, et al. An audit of ANCA in routine clinical practice. Postgrad Med J 1995;71:605-612.
7. Edgar JDM. The clinical utility of ANCA positivity. Ann Rheum Dis 1996;55c:494-6.
8. Zauli D, Grassi A, Ballardini G, et al. Testing for antineutrophil cytoplasmic antibodies. Am J Clin Pathol 2000;113:445-6.
9. Savige J, Gillis D, Benson E, et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 1999;111:507-13.
10. Mandl LA, Solomon DH, Smith EL, et al. Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis: can test-ordering guidelines improve diagnostic accuracy? Arch Intern Med 2002;162:1509-14.
11. McLaren JS, Stimson RH, McRorie ER, et al. The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting. QJM 2001;94:615-21.
12. Segelmark M, Westman K, Wieslander J. How and why should we detect ANCA? Clin Exp Rheumatol 2000;18:629-35.
13. Hedger NA, Roderick P, Drey N, et al. Incidence and outcome of pauci-immune rapidly progressive glomerulonephritis (RPGN) in Wessex, UK - a ten year retrospective study. Nephrol Dial Transplant 2000;15:1593-9.